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Abstract
Background: Postmenopausal hormone therapy (HT) influences endogenous hormone concentrations and
increases the risk of breast cancer. Gene expression profiling may reveal the mechanisms behind this relationship.
Our objective was to explore potential associations between sex hormones and gene expression in whole blood
from a population-based, random sample of postmenopausal women
Methods: Gene expression, as measured by the Applied Biosystems microarray platform, was compared between
hormone therapy (HT) users and non-users and between high and low hormone plasma concentrations using
both gene-wise analysis and gene set analysis. Gene sets found to be associated with HT use were further
analysed for enrichment in functional clusters and network predictions. The gene expression matrix included 285
samples and 16185 probes and was adjusted for significant technical variables.
Results: Gene-wise analysis revealed several genes significantly associated with different types of HT use. The
functional cluster analyses provided limited information on these genes. Gene set analysis revealed 22 gene sets
that were enriched between high and low estradiol concentration (HT-users excluded). Among these were seven
oestrogen related gene sets, including our gene list associated with systemic estradiol use, which thereby
represents a novel oestrogen signature. Seven gene sets were related to immune response. Among the 15 gene
sets enriched for progesterone, 11 overlapped with estradiol. No significant gene expression patterns were found
for testosterone, follicle stimulating hormone (FSH) or sex hormone binding globulin (SHBG).
Conclusions: Distinct gene expression patterns associated with sex hormones are detectable in a random group
of postmenopausal women, as demonstrated by the finding of a novel oestrogen signature.
Background
Previous reports have shown that there is an association
between plasma/serum concentrations of endogenous
sex hormones and the risk of breast cancer among post-
menopausal women [1-3]. The Women’sH e a l t hI n i t i a -
tive [4] and large observational studies [5,6] have also
shown that use of postmenopausal hormone therapy
(HT) increases the risk of breast cancer. Exogenous hor-
mones have an influence on endogenous hormone con-
centrations. Systemically administered HT containing
estradiol (E2) suppresses plasma concentrations of folli-
cle stimulating hormone (FSH) and increases E2 and sex
hormone binding globulin (SHBG) concentrations [7-9].
Tibolone use suppresses both FSH and SHBG concen-
trations in blood and increases free testosterone (T)
because of lower SHBG levels [10,11].
Blood is a fluid connective tissue that interacts with all
other human tissues, and peripheral blood cells have
been found to reflect system wide biology [12,13]. Being
easily accessible, peripheral blood can be an excellent
surrogate tissue for exploring the effects of environmen-
tal exposure on gene expression in large epidemiological
studies. Microarray analysis of the blood transcriptome
may shed light on the etiologic pathways connecting
environmental exposure and disease [13], and gene
expression signatures are hypothesised to become
important diagnostic tools or prognostic biomarkers
[14].
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Women and Cancer study (NOWAC) [15,16], popula-
tion-based studies on whole blood gene expression in
postmenopausal women are scarce. However, some
research on blood cells or tissue biopsies has reported
gene expression patterns associated with HT and other
menopause-related variables [17-22].
The population-based NOWAC postgenome cohort
study provides opportunities for conducting nested case-
control studies using gene expression analyses of whole
blood [23]. A first step would be to assess the pre-
disease impact of known risk factors for female cancer
(e.g., circulating sex hormone levels, or HT) on gene
expression.
The objective of this study was to explore potential
associations between different levels of endogenous and
exogenous sex hormones andg e n ee x p r e s s i o ni nw h o l e
blood from a random sample of postmenopausal
women.
Methods
Subjects
An extensive description of NOWAC has been pub-
lished elsewhere [24]. Briefly, NOWAC is a national,
population-based cohort study among women 30-70
years old, with questionnaire data on lifestyle and health
collected at 4-6 year intervals.
The participants were randomly drawn from the Nor-
wegian Central Population Register. By June 2007,
approximately 172 000 women were enrolled in
NOWAC overall. The study complied with the Declara-
tion of Helsinki and all participants gave written
informed consent. The study was approved by the
Regional Committee for Medical and Health Research
Ethics and the Norwegian Data Inspectorate. The
NOWAC postgenome cohort comprises questionnaire
data and blood samples collected during the 2003-2006
period from approximately 50 000 women born from
1943 to 1957 [23]. See Additional file 1 for a copy of
the questionnaire (translated). For the present analyses,
we used a randomly drawn group of 445 third-time par-
ticipants from the NOWAC postgenome cohort who
donated a blood sample in 2005 (Figure 1). The overall
response rate was 74%. The exclusion of subjects with
incompletely filled blood collection tubes, >3 days from
blood collection to frozen sample or pre-/perimenopau-
sal status, left 328 PAXgene (PreAnalytiX GmbH, Hem-
brechtikon, Switzerland) whole blood samples for RNA
extraction.
Endogenous hormones measurements
Plasma concentrations of estradiol (E2), progesterone
(P4), testosterone (T), follicle stimulating hormone
(FSH) and sex hormone binding globulin (SHBG) were
measured by immunometry, as described in a previous
report[7]. For convenience, SHBG is referred to as a
hormone throughout this text.
RNA isolation
Total RNA was isolated using the PAXgene Blood RNA
Isolation Kit, according to the manufacturer’sp r o t o c o l
(PreAnalytiX GmbH, Hembrechtikon, Switzerland). The
RNA quantity and purity were assessed by the Nano-
Drop ND-1000 spectrophotometer (ThermoFisher
Scientific, Wilmington, Delaware, USA). The absorbance
ratio for 260 nm and 280 nm (A260/A280) was between
1.93 and 2.1 for all of the samples included for further
analysis. The Experion automated electrophoresis system
(BioRad, Hercules, CA, USA) and the RNA StdSens
Analysis Kit were used to evaluate the RNA integrity of
a randomised 32% of the samples, according to the
manufacturer’s protocol. Thirty-nine samples were
excluded because of insufficient purity or yield.
Microarray-based profiling and image analysis
The samples were analysed using the Applied Biosys-
tems expression array system (Foster City, LA, USA).
From each sample, 500 ng of total RNA was amplified
using the NanoAmp RT-IVT labelling kit for one round
of amplification (Applied Biosystems), in accordance
with the manufacturer’s protocol. The quantity and pur-
ity of the cRNA was measured using the NanoDrop
ND-1000. Digoxigenin (DIG)-labelled cRNA, 10 μgp e r
sample, was fragmented and hybridised to the Applied
Biosystems Human Genome Survey Microarray V2.0, in
Figure 1 Study population.
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Protocol. Each microarray chip contained 277 control
probes and 32 878 probes representing 29 098 genes.
The Applied Biosystems Expression System software
was used to extract signal intensities, signal to noise
ratios (S/N) and flagging values from the microarray
images.
Data analysis
T h ed a t aw e r ea n a l y s e du s i n gRv e r s i o n2 . 8 . 1( h t t p : / /
cran.r-project.org) and tools from the Bioconductor
project (http://www.bioconductor.org). For genes with
a flagging value >8191, the expression intensity was
set to missing. Three samples where less than 40% of
the probes showed S/N ≥3 were excluded. Probes with
S/N ≥3 in less than 50% of the samples were filtered
out. We subsequently performed log transformation,
quantile normalisation, and imputation of missing
values using the k-nearest neighbourhood method
(k = 10). The gene expression values were adjusted for
significant technical variables (i.e., array lot number,
RNA extraction date and time between blood
collection and storage) using gene-wise mixed linear
modelling [25]. One sample was excluded as an outlier
because of high plasma E2 and P4 concentrations,
which was probably due to misclassification of meno-
pausal status. The final expression matrix comprised
285 samples and 16 185 probes. The microarray data
have been deposited at Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo), accession
number GSE15289.
The effect of different HT regimens and hormone
concentrations on the expression of individual genes
was tested using a linear model, limma[26], adjusted for
multiple testing using the false discovery rate (FDR)
[27].
The gene sets defined from the limma analyses, which
were extracted from the literature or found in publicly
available web applications, such as KEGG (Kyoto Ency-
clopaedia of Genes and Genomes) [28] or AmiGO [29],
were tested for differential expression between groups
with high and low hormone concentration using globalt-
est [30]. The table in Additional File 2 lists all the 56
gene sets included in the analysis. The gene sets fulfill-
ing the criteria p < 0.05, FDR <0.25, and comparative p
< 0.20 were defined as differentially expressed. The
comparative p-value denotes the percentage of random
g e n es e t so ft h es a m es i z et h a tw o u l dh a v eal a r g e rt e s t
statistic than the gene set in question. The same method
w a su s e dt ot e s tf o rg e n es e te n r i c h m e n tb e t w e e nt h e
different categories of HT use versus non-use. Core
genes for each significant gene set were defined as the
genes with the highest influence on the differences seen
(with a cut-off of z.score >1.5).
The analyses were adjusted for the variables that
were significantly different between the groups in ques-
tion (i.e., age and/or body mass index (BMI)).
Information on specific genes was found at Gene-
Cards
® (http://www.genecards.org) [31]. Some genes
were not assigned an approved gene symbol and are
referred to as “unassigned” o rb yt h eC e l e r aG e n eI D ,i f
one was provided in the Applied Biosystems annotation.
The searches for gene networks and pathways were
performed using DAVID (the Database for Annotation,
Visualisation and Integrated Discovery) [32] and
HEFalMp (Human Experimental/Functional Mapper)
[33].
Endogenous hormones were analysed as dichotomised
variables: high (fourth quartile) versus low (first quartile)
of hormone concentration, with cut-offs defined among
the non-users of medication. Users of HT and thyroxine
(T4) were excluded from these analyses.
Exogenous hormones were categorised as use of sys-
temic E2 or E2 and progestogen (P) (tablets or patches),
systemic E2 alone (patches), tibolone or total HT.
Although not defined as postmenopausal HT, T4 use
was also defined as a category. The different types of
exogenous hormones were compared to non-use. Users
of other medication (e.g., blood pressure lowering
agents, antibiotics, antihistamines) were excluded from
these analyses.
Results
HT use
Among the 285 women, 182 were medication users (52
used HT and 159 used other medication). Table 1
shows the participant characteristics for the study
sample.
Table 2 shows the results from the limma analysis,
comparing different categories of HT with non-users
(users of other medication excluded). Five genes were
significantly associated with HT use, and nine genes
with FDR <0.28. The list of differentially expressed
genes associated with use of “E2 or E2/P systemic” treat-
ment was the longest (n = 33). The overlap between the
gene sets from the three HT categories that contain
estradiol is shown in Figure 2. Tibolone and T4 use
resulted in 400 and 8 differentially expressed genes,
respectively. Because of the limited number of tibolone-
only users (n = 2), a complementary analysis comprising
all tibolone users was conducted. With an FDR cut-off
at 0.50, we found 58 genes; no genes had FDR <0.41.
Among these 58 genes, 21 were significantly associated
with the tibolone-only users.
Using functional annotation clustering in DAVID, the
“E2 or E2/P systemic” gene set was enriched (enrichment
score 1.67) in one cluster that included six general cellu-
lar component GO terms. Among them was
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the lowest FDR (0.17). The “E2 alone” gene set and the
T4 gene set revealed no enriched clusters. HEFalMp pre-
dicted a few gene networks for the tibolone gene set
(Figure 3). The tibolone gene set revealed no signifi-
cantly enriched annotation clusters in DAVID. However,
one individual GO term, “alcohol metabolic process”
which was based on four genes (ALDH2, PRDX1, PDIA
and PNPO), was significant (FDR = 0.06).
High and low hormone concentrations
Comparing the high and low hormone concentrations
using a gene-wise approach (limma, HT and T4 users
excluded), two genes of unknown biological function
(DGCR9 and hCG2018460) were significantly differen-
tially expressed between high and low levels of FSH. No
genes were significant for any of the remaining hor-
mones. However, we observed significant gene set
enrichment between high and low concentrations of E2
and P4 (the table in Additional file 3, with HT and T4
users excluded).
Out of the 22 gene sets significant for E2,s e v e nw e r e
oestrogen or HT related, including the “E2 or E2/P sys-
temic” gene set. Seven gene sets extracted from four
publications were related to white blood cells and
immune response, and the remaining eight (from five
Table 1 Participant characteristics given as mean (SD) or frequency (%)
Age, years 55.7 (3.6)
BMI, kg/m
2 25.6 (4.3)
Among women not using medication
Sex hormone concentration 1.quartile (low)
Cut-off (mean)
4.quartile (high)
Cut-off (mean)
Estradiol nmol/L 0.10 (0.09) <0.05] (0.05) >0.08 (0.14)
Progesterone nmol/L 0.99 (0.67) <0.55] (0.44) >1.21 (1.79)
Testosterone nmol/L 1.16 (0.74) <0.66] (0.50) >1.54 (2.14)
FSH IU/L 70.2 (28.0) <56.4] (44.5) >91.2 (106.4)
SHBG nmol/L 47.6 (21.8) <32.0] (24.2) >61.0 (75.1)
Medication use 182 (64%)
HT 52 (18%)
E2 and E2/P systemic 32 (62%)
E2 systemic alone 9 (17%)
Tibolone 10 (19%)
Vaginal treatment 9 (17%)
Thyroxine 20 (7%)
Other medication 159 (56%)
No medication 98 (34%)
Number of medications used (n = 182)
1 medication 97 (53%)
2 medications 62 (34%)
>2 medications 23 (13%)
Current smoker
Yes 75 (26%)
No 209 (73%)
Table 2 Number of genes differentially expressed between HT users and non-users (in the Limma analysis)
HT type Total sample N Single users
1 N Number of genes FDR <0.25
HT all types 52 23 5(9)
2
E2 or E2/P systemic 32 15 33
E2 systemic 9 7 10
Tibolone 10 2 400
Tibolone2
3 10 10 0(58)
3
Thyroxine 20 5 8
Non-users 98 98
1 Users of other medication excluded.
2 FDR <0.28, 5 genes with FDR <0.25.
3 All tibolone users were included in the analysis; there were 58 genes with FDR <0.50.
Waaseth et al. BMC Medical Genomics 2011, 4:29
http://www.biomedcentral.com/1755-8794/4/29
Page 4 of 10publications) were related to proto-oncogenes, exercise,
age, consuming a carbohydrate/protein breakfast, tran-
scription factors and drug metabolising enzymes.
Among the 15 gene sets differentially expressed for P4,
11 were also significant for E2, although with slight
differences in the core genes. Among the 186 different
core genes, 151 (81%) were up-regulated in women with
low E2/P4 concentrations. Among these, 71 (47%) were
present for E2, 34 (23%) were present for P4 and 45
(30%) appeared on both lists. Among the 35 core genes
up-regulated in women with high E2/P4 concentrations,
19 (54%) genes were present for E2, 14 (40%) were pre-
sent for P4 and 2 (6%) were on both lists. When investi-
gating FSH, SHBG and T, no gene set fulfilled all three
criteria for differential expression in the gene set analy-
sis. Of note, the same analysis conducted without
excluding HT and thyroxine users only marginally
altered the ranking of the gene sets by p-value, but the
p-values and FDRs increased slightly (data not shown).
Our “E2 or E2/P systemic” gene set was only signifi-
cant for E2, and therefore it represents a novel oestrogen
gene expression signature. Among the six core genes for
the “E2 or E2/P systemic” gene set (Figure 4), five had
unknown function, while RAI1 may function as a tran-
scription regulator. Comparing the direction of gene
expression (up- or down-regulation) for the “E2 or E2/P
systemic” gene set between endogenous and exogenous
E2 (Figures 2 and 4), we found 61% concordance for all
33 probes and 80% concordance among the 10 most
influential probes. The second most influential gene
(C3orf14) was up-regulated in high E2 but down-regulated
among users of systemic E2 relative to non-users. Gene
Figure 2 The three gene sets (circles) found when comparing different categories of HT users with non-users. The partly overlapping
circles show which genes were significant for one, two or all three HT categories. All three categories include users of systemic E2. Gene
symbols in red denote genes up-regulated in users and gene symbols in green denote genes up-regulated in non-users. Among the 9 HT
genes, LOC344178, SET, MGC4618 and MORC2 have FDR <0.28, the remaining 5 genes have FDR <0.25.
Figure 3 The tibolone gene set (21 genes) in HEFalMp.T h e
network between core genes (in grey) related to tibolone use and
genes (in white) predicted by Hefalmp in relation to this query,
considering all genes in all biological processes.
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E2 but up-regulated among users of systemic E2.N o n eo f
the five genes that overlapped between the “E2 alone” and
“E2 or E2/P systemic” gene sets (Figure 2) were among the
six core genes; they were ranked as numbers 8, 9, 12 and
21 (Figure 4).
Discussion
This study confirms that a population based cohort
study such as NOWAC provides the opportunity to use
high throughput technology (e.g., microarray analysis) to
explore biologic variation in gene expression related to
both endogenous and exogenous sex hormones.
According to the gene-wise analysis, hormone concen-
trations did not show a profound influence on gene
expression. This result is not surprising, given the low
variability that is present in a study group representing
the general postmenopausal population. Conversely, all
categories of HT use produced differentially expressed
genes when compared with non-users. This finding is
attributable to the wider range of hormone concentra-
tions between the groups in this analysis. Intake of exo-
genous E2, particularly by systemic administration,
increases endogenous plasma E2 and suppresses plasma
FSH toward premenopausal levels [7]. Apart from the
direct hormonal effects, a probable cause is the supply
of synthetic medical substances (e.g., tibolone, progesto-
gens and their metabolites) to the blood. The overlap
between the gene sets shown in Figure 2 was probably
caused by the overlap of subjects; all of the women
using systemic E2 alone are included among the women
using E2P systemic, who are again included among the
HT-users. Also, these genes seem the most stable, as
they remain significant even if the sample group compo-
sition is changed. The minimal information on gene
function for the two E2 gene sets in DAVID could be
due to the nature of gene-wise analysis, which assumes
that genes are expressed independently of each other.
The gene set enrichment analysis showed a fair
amount of overlap between P4 and E2, a plausible result
considering the positive correlation between the two
hormones (r = 0.43, p < 0.01). Among the 58 subjects
present in both the E2 and the P4 analyses, 49 were con-
cordantly in the low or high group for both hormones.
Hence, it may be difficult to disentangle gene expression
associated with E2 and P4.S t i l l ,t h e r ea r es o m e
Figure 4 Gene plot of the “E2 or E2/P systemic” gene set (33 genes) in relation to E2 concentration ("0” =l o w ,“1” =h i g h ) .T h e
reference line for each bar represents the expected height under the null hypothesis (i.e., that the gene is not associated with hormone
concentrations). The marks indicate the number of standard deviations above the reference line.
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gene set (Frasor/KEGG) was only significant for E2,a n d
although the total “oestrogen regulated” gene set (Fra-
sor/KEGG) was significant for both E2 and P4, there was
no overlap between the core genes up-regulated in the
high group. In general, we found a much larger overlap
of core genes up-regulated in the low than in the high
group for the gene sets that were significant for both
hormones.
The “E2 or E2/P systemic” gene set turned out to be a
more reliable oestrogen signature than the “E2 alone”
gene set, probably because of the inclusion of oral high-
dose E2 users (n = 7) and/or the generally larger group
of users in the “E2 or E2/P systemic” category. Interest-
ingly, as opposed to most of the other significant gene
sets, the majority of the genes in this gene set were up-
regulated in the high E2 g r o u p .T h e r ew a sah i g h ,
although not complete, concordance in the direction of
gene expression between endogenous and exogenous E2
for this gene set. Opposing directions for some genes
may have been due to the progestogen content in sev-
eral of the products in this HT category, or possibly dif-
ferential feedback mechanisms between endogenous and
exogenous hormones. Further research may reveal the
functions and regulation of these core genes.
In addition to the core genes, interesting single genes
in the “E2 or E2/P systemic” gene set included PNRC2,a
coactivator of nuclear receptors such as the ESRRs (oes-
trogen related receptors), and CSMD2, which has been
previously found to be differentially expressed in HT
users [15]. Among the remaining genes aspiring to, but
not quite reaching, core gene status (Figure 4), are also
VPS37A (no. 8), RNF139 (No. 9) and CNOT7 (No. 12),
indicating that these overlapping genes from Figure 2
are worthy of further research into their association
with sex hormones. Noteworthy in the “E2 alone” gene
set is the TSC22D1 gene, whose protein product may
p l a yar o l ei nr e s i s t a n c et o w a r dT a m o x i f e n
® treatment
in breast cancer patients[34]
The tibolone and thyroxine gene sets did not meet our
significance criteria for any of the hormones. One might
have expected some association with FSH, but the num-
ber of users in these two categories was probably too
small to generate reliably specific expression sets.
None of the gene sets were differentially expressed
between high and low levels of FSH, SHBG or T. Com-
pared with the wide variety of target tissues and the
acknowledged effects of steroid hormones, FSH and
S H B Gw o u l db ee x p e c t e dt oh a v eam o r el i m i t e da s s o -
ciation with gene expression. The biological effect of
FSH is essentially the stimulation of gonadal E2 and P4
synthesis, and in postmenopausal women FSH has lost
its gonadotropic potency. Although it has been sug-
gested that SHBG possesses some signalling properties
[35], it is mainly a transport protein. Adding the moder-
ate variation in FSH and SHBG levels across the study
population, a difference in gene expression might be dif-
ficult to detect. Testosterone is not a major hormone in
women. Although it is a potent steroid, the differences
in gene expression relative to low levels of T are prob-
ably not detectable in a setting with high background
variability.
Seven gene sets related to immune responses or cells
active in the immune system were differentially
expressed between the high and low E2 concentration
groups. Additionally, two gene sets associated with exer-
cise (stress response and inflammatory response) and
t h ep r o t o - o n c o g e n eg e n es e tc o u l db ev i e w e da s
immune system related. Sex hormones have been found
to influence the immune system through steroid recep-
tors in white blood cells [36]. In general, female sex hor-
mones are viewed as suppressors of the immune
response. It has been shown that plasma levels of both
interleukin 6 (IL6) and interleukin 2 (IL2) increase after
menopause (i.e., with decreasing levels of E2)a n dt h a t
HT opposes this effect [36]. Although neither IL6 nor
I L 2w e r ea m o n gt h e1 61 8 5p r o b e si no u rd a t as e t ,t h e
higher expression of the respective receptors, IL6R and
IL2R, at low E2 concentrations indicates the suppressive
effects of E2. Other interesting core genes include the
heat shock proteins (HSPs) in the “stress response from
exercise” gene set. The HSPs function as intracellular
chaperones for other proteins (integrity and folding),
a n ds o m eh a v eb e e nf o u n dt op l a yar o l ei nt h er a p i d
non-genomic effects of steroid hormones [37], which is
interesting in light of the rapid responses seen in these
genes following exercise [38]. FOS is a high-influence
core gene for both E2 and P4.I nf a c t ,a l lo ft h e
FOS-containing gene sets were differentially expressed.
However, contradictory to Frasor et.al. [39], FOS was
up-regulated in the low E2 group, together with
EPB41L3 and AP1G1.B yc o n t r a s t ,CXCL12,t h es t e r o i d
21-hydroxylase CYP21A2 and PDZK1 were congruously
up-regulated in the high-E2 group. According to Kendall
et al. [20], FOS is up-regulated by oestrogen deprivation,
which supports our results, while SGK3 and TAGLN are
down-regulated, which contradicts our results. These
contradictions in gene expression direction may arise
from methodological differences or from regulatory and
feed-back mechanisms similar to the above mentioned
discordance for the “E2 or E2/P systemic” gene set.
Though the differential expression of the tibolone
gene set lacked statistical significance, the network
mapping suggested that further research is warranted.
Interesting single genes included COMT,ac e n t r a l
enzyme in the metabolism of oestrogens; and SOAT1,
an intracellular protein that forms cholesterol esters
from cholesterol, thereby possibly contributing to
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tibolone users, in accord with the known increased risk
of stroke associated with tibolone use [40]. A larger data
set would contain a larger group of tibolone users and
provide a more solid basis for finding tibolone asso-
ciated genes.
Strengths and limitations
The NOWAC study subjects were randomly drawn from
the Central Population Register and are representative of
the population in which future microarray based diag-
nostic and/or prognostic tests for breast cancer will be
applied. Our ability to detect subtle effects in a dataset
with a high degree of random variation is reassuring.
Among the limitations of this study is the lack of
information regarding the relative proportions of periph-
eral blood cell types. If differences in hormone concen-
trations or HT use are associated with the numbers of
particular type(s) of peripheral blood cells, it may have
influenced our results. Research into the influence of
sex hormones on leukocyte cell count reveals conflicting
results [36]. Although the women were healthy enough
to visit a physician’s office, we had limited information
regarding disease and immune system status beyond
w h a tc o u l db ei n f e r r e df r o mt h es e l f - r e p o r t e dd r u gu s e .
However, a systematic difference in disease prevalence
between hormone concentration levels is unlikely.
Our FDR cut-off of <0.25 may have exceeded conven-
tional limits, whereas FDR≤0.10 is considered acceptable
[41]. A higher FDR can be accepted, however, at least
when analysing gene sets extracted from previous publi-
cations and thereby supported by research. Also, we
were not looking for single genes in the gene-wise ana-
lyses but for groups of genes that may have explained
known effects. For example, among the 33 genes in the
“E2 or E2/P systemic” gene set, 9 had FDR≤0.10, but
only two of these genes were among the core genes dif-
ferentially expressed between the high and low E2
g r o u p .H e n c e ,i fw eh a du s e dt h e≤0.10 FDR cut-off we
might have overlooked this oestrogen signature.
Our results are based on a snapshot measurement; we
have only one blood sample from each woman and can
infer nothing about intra-individual variation or varia-
tion over time. However, previous reports have shown
low intra-individual variation in gene expression com-
pared with inter-individual variation [42,43].
The study design prevented an extensively standar-
dised blood sampling protocol with regards to fasting,
blood sample handling and transport, etc. However, the
main source of technical variation in this data set was
associated with the performance of the assay and not
with pre-analytical processing[25].
The gene set enrichment analyses were adjusted for
age and/or BMI. We found no significant differences
between the compared categories with respect to fasting
and smoking. However, residual confounding may have
influenced the differences found between high and low
concentrations of E2 and P4.
Differentially expressed genes have not been validated
using an independent data set, and our results should
be interpreted accordingly.
Conclusions
Through exploring potential associations between sex
hormones and gene expression, we have identified a
novel oestrogen gene expression signature, and further
research may reveal the function of these genes in rela-
tion to E2. A potential tibolone signature was also defined
that warrants further research. Several gene sets, particu-
larly those oestrogen and immune system related but
also gene sets related to drug metabolism, exercise and
carbohydrate/protein ingestion, were differentially
expressed between high and low levels of E2 and P4.
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the blood draw.
Additional file 2: Gene sets included in the gene set enrichment
analysis. This is a Word table showing all the 56 gene sets included in
the analysis. The gene sets are categorised as related to female sex
hormone or menopause, as related to blood cells and the immune
system, or, as related to other factors.
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